[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618642":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":12,"responsibleParty":34,"collaborators":36,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":15,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Radboud University Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"High-risk localized prostate cancer or high-risk locally advanced prostate cancer",null,"Included patients will have:\n\n1. High-risk localized prostate cancer, with PSA level \\>20 ng\u002FmL, Gleason score 8-10 (ISUP grade 4\u002F5) at prostate biopsies, or iT3a (based on multi-parametric MRI of the prostate); or\n2. High-risk locally advanced prostate cancer, having any PSA level, any Gleason score\u002FISUP grade, iT3b-4 (based on multi-parametric MRI of the prostate) or iN1 (based on PSMA PET\u002FCT imaging).",[13],{"facility":14,"status":15,"city":16,"state":10,"zip":10,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":25},"Prosper Prostate Cancer Clinics","RECRUITING","Nijmegen","Netherlands","NL",{"type":20,"coordinates":21},"Point",[22,23],5.85278,51.8425,{"lat":23,"lon":22},[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"M.J. van der Doelen, MD, PhD","CONTACT","+31 24 365 8961","m.vanderdoelen@cwz.nl",{"name":32,"role":28,"phone":10,"phoneExt":10,"email":33},"Niven Mehra, MD, PhD","Niven.Mehra@radboudumc.nl",{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[37,39,41],{"name":38,"class":6},"Catharina Ziekenhuis Eindhoven",{"name":40,"class":6},"Canisius-Wilhelmina Hospital",{"name":42,"class":6},"Maxima Medical Center","100618642","detection-of-minimal-residual-disease-post-prostatectomy-100618642",false,"NCT07334275","Detection of Minimal Residual Disease Post-prostatectomy","Pilot Study for the Detection of Minimal Residual Disease Post-prostatectomy and Early Disease Recurrence in Circulating Tumor DNA to Guide Future Adjuvant Therapy in High-risk Prostate Cancer Patients (MiRaDE)","MiRaDE","Inclusion Criteria:\n\n* Male aged 18 years or older;\n* High-risk prostate cancer, defined as:\n\n  1. High-risk localized prostate cancer, with PSA level \\>20 ng\u002FmL, Gleason score 8-10 (ISUP grade 4\u002F5) at prostate biopsies, or iT3a (based on multi-parametric MRI of the prostate); or\n  2. High-risk locally advanced prostate cancer, having any PSA level, any Gleason score\u002FISUP grade, iT3b-4 (based on multi-parametric MRI of the prostate) or iN1 (based on PSMA PET\u002FCT imaging);\n* Scheduled for robot-assisted radical prostatectomy;\n* Willingness to consent to both patient information sheets regarding tissue and liquid biobanking.\n\nExclusion Criteria:\n\n* Relevant contra-indications that may limit clinical follow-up or blood collection, as assessed by the including physician.","MALE","18 Years",{"count":54,"type":55},50,"ESTIMATED","OBSERVATIONAL","The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.",[59],"Prostate Cancer",[61,62,63],"Prostate cancer","Prostatectomy","Circulating tumor DNA","2025-12-31",{"date":66,"type":67},"2026-01-12","ACTUAL",{"date":69,"type":67},"2025-09-16",{"date":71,"type":55},"2028-01",{"name":5,"class":6},1]